BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 16465382)

  • 21. Triptolide sensitizes resistant cholangiocarcinoma cells to TRAIL-induced apoptosis.
    Panichakul T; Intachote P; Wongkajorsilp A; Sripa B; Sirisinha S
    Anticancer Res; 2006; 26(1A):259-65. PubMed ID: 16475706
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1).
    Chopin V; Slomianny C; Hondermarck H; Le Bourhis X
    Exp Cell Res; 2004 Aug; 298(2):560-73. PubMed ID: 15265702
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histone deacetylase inhibitors promote osteoblast maturation.
    Schroeder TM; Westendorf JJ
    J Bone Miner Res; 2005 Dec; 20(12):2254-63. PubMed ID: 16294278
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histone deacetylase inhibitors and aspirin interact synergistically to induce cell death in ovarian cancer cells.
    Sonnemann J; Hüls I; Sigler M; Palani CD; Hong le TT; Völker U; Kroemer HK; Beck JF
    Oncol Rep; 2008 Jul; 20(1):219-24. PubMed ID: 18575740
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors.
    VanOosten RL; Earel JK; Griffith TS
    Cancer Gene Ther; 2006 Jun; 13(6):628-32. PubMed ID: 16456549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies.
    Inoue S; MacFarlane M; Harper N; Wheat LM; Dyer MJ; Cohen GM
    Cell Death Differ; 2004 Dec; 11 Suppl 2():S193-206. PubMed ID: 15608694
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors.
    Facchetti F; Previdi S; Ballarini M; Minucci S; Perego P; La Porta CA
    Apoptosis; 2004 Sep; 9(5):573-82. PubMed ID: 15314285
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines.
    Lillehammer T; Engesaeter BO; Prasmickaite L; Maelandsmo GM; Fodstad O; Engebraaten O
    J Gene Med; 2007 Jun; 9(6):440-51. PubMed ID: 17410615
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic apoptosis induction by proteasome and histone deacetylase inhibitors is dependent on protein synthesis.
    Drexler HC; Euler M
    Apoptosis; 2005 Aug; 10(4):743-58. PubMed ID: 16133866
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.
    Heider U; Kaiser M; Sterz J; Zavrski I; Jakob C; Fleissner C; Eucker J; Possinger K; Sezer O
    Eur J Haematol; 2006 Jan; 76(1):42-50. PubMed ID: 16343270
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels.
    Nawrocki ST; Carew JS; Douglas L; Cleveland JL; Humphreys R; Houghton JA
    Cancer Res; 2007 Jul; 67(14):6987-94. PubMed ID: 17638911
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells.
    Sung ES; Kim A; Park JS; Chung J; Kwon MH; Kim YS
    Apoptosis; 2010 Oct; 15(10):1256-69. PubMed ID: 20582477
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ionizing radiation but not anticancer drugs causes cell cycle arrest and failure to activate the mitochondrial death pathway in MCF-7 breast carcinoma cells.
    Jänicke RU; Engels IH; Dunkern T; Kaina B; Schulze-Osthoff K; Porter AG
    Oncogene; 2001 Aug; 20(36):5043-53. PubMed ID: 11526489
    [TBL] [Abstract][Full Text] [Related]  

  • 34. E1A sensitizes cancer cells to TRAIL-induced apoptosis through enhancement of caspase activation.
    Shao R; Lee DF; Wen Y; Ding Y; Xia W; Ping B; Yagita H; Spohn B; Hung MC
    Mol Cancer Res; 2005 Apr; 3(4):219-26. PubMed ID: 15831675
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An MMP-2/MMP-9 inhibitor, 5a, enhances apoptosis induced by ligands of the TNF receptor superfamily in cancer cells.
    Nyormoi O; Mills L; Bar-Eli M
    Cell Death Differ; 2003 May; 10(5):558-69. PubMed ID: 12728254
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition.
    Totzke G; Schulze-Osthoff K; Jänicke RU
    Oncogene; 2003 Sep; 22(39):8021-30. PubMed ID: 12970750
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA.
    Kim MS; Blake M; Baek JH; Kohlhagen G; Pommier Y; Carrier F
    Cancer Res; 2003 Nov; 63(21):7291-300. PubMed ID: 14612526
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of apoptosis in renal tubular cells by histone deacetylase inhibitors, a family of anticancer agents.
    Dong G; Wang L; Wang CY; Yang T; Kumar MV; Dong Z
    J Pharmacol Exp Ther; 2008 Jun; 325(3):978-84. PubMed ID: 18310471
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL.
    Butler LM; Liapis V; Bouralexis S; Welldon K; Hay S; Thai le M; Labrinidis A; Tilley WD; Findlay DM; Evdokiou A
    Int J Cancer; 2006 Aug; 119(4):944-54. PubMed ID: 16550602
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Crosstalk between extrinsic and intrinsic cell death pathways in pancreatic cancer: synergistic action of estrogen metabolite and ligands of death receptor family.
    Basu A; Castle VP; Bouziane M; Bhalla K; Haldar S
    Cancer Res; 2006 Apr; 66(8):4309-18. PubMed ID: 16618756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.